Flat-cylindrical tablets, scored and chamfered, white to off-white colors. On the flat side with a risk, the inscription MATERIA MEDICA is applied, on the other flat the side is marked with the inscription AFALAZA.
Afalase® is indicated for use in adults.
Benign prostatic hyperplasia.
Dysuric disorders (as part of complex therapy): frequent urge to
urination, difficulty urinating, pain and discomfort in the area
perineum accompanying benign prostatic hyperplasia.
inside. 2 tablets, 2 times a day, morning and evening (keep in mouth until full
dissolution - outside the meal). The notch is not intended for dividing the tablet into parts.
In dysuric disorders, the drug is recommended to be taken within 16 weeks.
On the recommendation of a doctor for severe pain and dysuric disorders
in the first 2-3 weeks of therapy, the drug is indicated up to 4 times a day.
To prevent prostate growth in patients with BPH and reduce the risk of
progression of the disease, the drug is recommended to be taken 2 times a day, in the morning and
evening for 12 months.
